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ABSTRACT The annual European Respiratory Society (ERS) International Congress (held in Paris in
2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge
techniques and innovative new therapies within the respiratory field. This article discusses only some of
the high-quality research studies presented at this year’s Congress, with a particular focus on airway
diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as
presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish
the key take-home messages of these studies, compare their findings and place them in the context of
current understanding.
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CONGRESS HIGHLIGHTS
AIRWAY DISEASE
Asthma
Basic and translational data
Asthma is one of the most common inflammatory diseases globally and affects over 200 million people
worldwide [1]; however, little is known regarding the detailed mechanisms driving the disease [2].
Asthmatic disease shows a high degree of heterogeneity [3] and this topic was elegantly addressed by Prof.
Sally Wenzel in her talk “Molecular phenotyping of asthma comes of age” in the symposium “State of the
art session: airways disease”. In line with this, NAWIJN et al. [4] showed, using single cell RNA sequencing,
that direct comparison of airway wall cells from asthmatic patients and healthy controls revealed selective
loss of well-differentiated ciliated cells accompanied by an increase in basal cells in asthma. Specific
inflammatory cell patterns were also observed in asthma and TOKUNAGA et al. [5] presented that CD163, a
scavenger receptor expressed on macrophages, was significantly increased in asthma death patients
compared to control subjects. They also confirmed in a mouse model of allergic inflammation that airway
hyper-responsiveness (AHR) and the number of eosinophils in bronchoalveolar lavage fluid (BALF) were
significantly decreased in CD163 deficient mice when compared with control wild-type mice. This
indicates an important role for altered phenotypes of macrophages not only in chronic obstructive
pulmonary disease (COPD), as previously reported, but also in asthma. It is evident that overlap between
the inflammatory response in asthma and COPD exists, especially when it comes to patients who smoke.
SILBERBRANDT et al. [6] reported that, in a severe asthma cohort with predominantly late-onset asthma,
airway eosinophilia was significantly associated with a smoking history of ⩾10 pack-years. They concluded
that further research was needed to explore underlying mechanisms driving eosinophilic airway
inflammation in severe asthma. Another factor in phenotyping asthma is age of onset and MISTRY et al. [7]
showed that there are phenotypic differences between early-onset and adult-onset difficult asthma. They
showed that early-onset difficult asthma is more common in females and associated with more atopy,
functional comorbidity, biologic therapy and healthcare need. Adult-onset difficult asthma meanwhile is
more common in males associated with smoking and comorbid lung disease. Mapping clinical phenotypes
and correlating them to molecular endotypes and inflammatory patterns will be of great importance to
increase our knowledge of mechanisms driving asthmatic disease as well as treatment strategies.
Much focus during the 2018 European Respiratory Society (ERS) International Congress was on the
mechanistic understanding of cell–microbe communications in the lung micro-environment and how they
promote airway disease or protect patients from it. The symposium “Cross-talk in the lung
microenvironment: implications for chronic lung disease” (session 218) focused on different aspects of the
cellular communication mechanisms in the lung that participate in health and disease, with presentations
by Profs. D. Davies, P. Hansbro, S. Krauss-Etschmann and S. Gabrielsson. The 2018 ERS International
Congress also had a “Meet the Expert” session on the topic “Lung microbiome: study design and
standardisation” (ME2). Lately, a shift in focus away from microbial involvement in infections and toward
a role in physiology has been observed. For a long time the lungs of healthy individuals were considered to
be free from microbes and hence to lack a microbiome. However, while the lung microbiota has a low
density, the maintenance of small numbers of bacteria seems to be a critical determinant of good health
[8]. POTACZEK et al. [9] demonstrated that interleukin (IL)-6, a central cytokine of innate immunity
responses, seems to be important for the ability to modulate the adaptive immune system in a non-allergic
Type-2 T-helper cell (Th2) direction. They also showed that IL-6 plays a specific role in mediating the
development of protective, anti-allergic mechanisms related to prior Acinetobacter lwoffii exposure.
Probiotics can be considered nonspecific adjuvants of innate immune response by modulating the Type-1
T-helper cell (Th1)/Th2 balance. AIMBIRE et al. [10] showed that probiotic Lactobacillus bulgaricus
mediated an anti-inflammatory effect in an experimental mouse model of allergic inflammation. They
showed that dendritic cell expression of CD86 as well as the Toll-like 4 receptor was increased after oral
administration of L. bulgaricus. In addition, L. bulgaricus attenuated eosinophil infiltration, mucus
production and specific IgE concentration in serum, and also inhibited secretion of IL-4, IL-5, IL-13 and
eotaxin in BALF. In a clinical study DE BOER et al. [11] presented interesting data from the BREATHE study
where bacterial lysates showed positive effects in the prevention of asthma exacerbations in patients with
severe asthma.
Clinical studies
Asthma is a heterogeneous inflammatory airway disease and the majority of asthmatics (59%) treated in
general practice are uncontrolled [12]. When physicians recognise poor asthma control, an appropriate
change to therapy must be considered. At this year’s Congress, VAN DER MEER et al. [13] presented their
research on dynamic hyperinflation, which, independent of asthma severity, is associated with poorer
overall health, less well-being and impaired activity in daily life. Due to its major impact on activity in
everyday life, dynamic hyperinflation should be an important target for treatment in asthma patients in
the future.
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It is also well known that asthma is associated with accelerated rate of lung function decline. The
relationship between decline and airway inflammation among asthmatics has important therapeutic
implications. In a large cohort, BACKMAN et al. [14] found that adult asthmatics with higher levels of blood
eosinophils had a history of excess forced expiratory volume in 1 s (FEV1) decline compared to
non-eosinophilic asthmatics, independent of other factors such as inhaled corticosteroid (ICS) use. GRAFF
et al. [15] presented similar results and their observations go further, showing that an evolution towards
an increase in blood eosinophils over time predicts accelerated FEV1 decline. They further confirmed that
this was independent of inflammatory phenotype or ICS treatment category.
A significant proportion of patients with difficult-to-control asthma remained nonadherent to corticosteroid
therapy [16]. ALAHMADI et al. [17] presented data from the U-BIOPRED study with the aim of investigating
the adherence of asthmatics according to the Medication Adherence Report Scale (MARS) and urinary
tests. One third of asthmatics reported sub-optimal adherence, while 42% of the severe asthmatics did not
have detectable urinary prednisolone or metabolites. In this study, there was very poor agreement between
MARS and urinary testing, suggesting that both approaches should be performed as part of a difficult
asthma assessment and are important before prescribing expensive novel biological therapies.
Moreover, multiple comorbidities are associated with asthma control, healthcare utilisation and quality of
life (QoL) in difficult asthma, and the data presented by AZIM et al. [18] demonstrated a high prevalence
of atopy, obesity, rhinitis and gastro-oesophageal reflux disease (GORD) in the Wessex Asthma Cohort. In
the area of personalised medicine there is increasing interest in the identification of treatable traits. The
analysis of the Australasian Severe Asthma Web-based Database revealed that treatable traits, such as
allergic sensitisation, upper-airway disease, airflow limitation, eosinophilic inflammation and frequent
exacerbations, are more common in severe asthma. Ten traits predicted exacerbation risk with the
strongest being frequent exacerbations, depression, inhaler-device polypharmacy, vocal cord dysfunction
and obstructive sleep apnoea (OSA) [19]. Psychological stress exacerbates clinical symptoms in patients
with asthma and stress has been previously shown to amplify the immune response to asthma triggers
[20]. The study by BACON et al. [21] provides evidence that acute stress negatively influences the
physiology of asthmatics. Stress did not affect the caliber of bronchi but was associated with decreased
carbon dioxide production, potentially suggesting hypocapnia and hyperventilation.
There are a lot of treatment options in the management of asthma; however, inhaled glucocorticoids
remain a cornerstone because of their efficacy, tolerability and rapid onset of action. Unfortunately, there
are patients in clinical practice who do not respond to ICS and predictors of such a poor response, such as
the absence of eosinophilic inflammation, have been highlighted previously [22]. MARCON et al. [23]
presented a study looking at FEV1 decline in asthma patients treated with ICS. Here, ICS use was
associated with increased FEV1 decline among subjects without sensitisation but not in sensitised
individuals. This suggests that a long-term ICS therapy may be more effective in preventing FEV1 decline
in allergic compared to non-allergic asthma [24].
After monitoring and treating comorbidities, 5–10% of the asthmatic population remains uncontrolled
despite high-dose glucocorticosteroids and bronchodilator medications. Here, we focus on data for
biologics presented at the 2018 ERS International Congress. Targeting IgE, omalizumab is able to reduce
exacerbations and improve asthma control and QoL in severe allergic asthmatics. The objective of the
study presented by HANNANIA et al. [25] was to evaluate the reduction of exacerbation in patients treated
with omalizumab according to their blood eosinophil counts (BECs). The reduction in exacerbations was
53% in patients with BECs greater than 300 per mm3 and 42% in patients with BECs less than 300 per
mm3, suggesting that BEC is not a good predictor of response to anti-IgE.
Monoclonal antibodies targeting cytokines or their receptors may induce the production of anti-drug
antibodies. ORTEGA et al. [26] have looked at the immunogenicity profile of mepolizumab during the Phase
III clinical development programme in severe asthma (COSMOS and COLUMBA). There was no
correlation between anti-drug antibody titres and change in BECs. Adverse events evaluated as potential
systemic allergic reactions were uncommon (2%) and unrelated to the study drug in antibody-positive
patients. WENZEL et al. [27] conducted a post hoc analysis of pooled data from the SIROCCO and
CALIMA studies on the effect of benralizumab in patients classified according to age of onset (<18, ⩾18
to <40 and ⩾40 years). They found a higher effect of benralizumab in adult-onset and late-onset asthma in
terms of FEV1 improvement or reduction in exacerbations as compared to early-onset asthma. This
suggests that adult-onset asthma with less atopy is the prime target population for anti-IL-5 therapy.
Approved for the treatment of moderate-to-severe atopic dermatitis, dupilumab is a fully human,
anti-IL-4R monoclonal antibody (mAb) that inhibits IL-4/IL-13. During the Congress, CORREN et al. [28]
presented their findings that dupilumab was more effective in asthmatics with chronic rhinosinusitis and
nasal polyps. In this sub-population, dupilumab significantly improved asthma control and QoL.
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Bronchial thermoplasty (BT) offers an alternative therapeutic option for severe asthmatics with persistent
symptoms requiring step five treatment in specialised centres. There is still a lack of data on predictors of
response to BT. During this Congress, TORREGO et al. [29] reported the results of the real-world BT Global
Registry study (including 159 patients). They suggested that healthcare utilisation decreased, clinical
outcomes improved and medication usage was reduced at 1 year after BT. FRIX et al. [30] also presented
that thermoplasty was well tolerated, with an improvement in pre- and post-FEV1 together with a
reduction in exacerbation rate and in the average dose of oral corticosteroids (OCS) in severe
non-T2-asthmatics. In addition, GOORSENBERG et al. [31] presented data on BT-treated patients and showed
that lung function parameters were unchanged after BT. However, a higher airway resistance was observed
in non-responders suggesting that a high resistance at baseline could be a negative predictor for BT
response. Furthermore, SANO et al. [32] presented BT data showing that responders to BT exhibited higher
R5 and R5-R20 (where R5 is the total respiratory system resistance, measured at 5 Hz and R20 is the
central resistance, measured at 20 Hz) at baseline compared to the non-responders. The responders also
exhibited a decrease in resistance compared to the non-responders 1 year after BT treatment.
COPD
Biomarkers
There is an unmet clinical need in COPD for biomarkers which reflect disease activity (i.e. future
exacerbations and rate of lung function decline) or predict treatment responsiveness. Blood eosinophils are
surrogate markers for airway eosinophilia [33] and previous studies have showed that patients with higher
BECs benefit from a reduction in exacerbations when treated with ICS-containing regimes (ICS/
long-acting β-agonist (LABA) or ICS/LABA/long-acting muscarinic antagonist (LAMA)). There are still
some uncertainties which have to be clarified regarding BEC, as follows: 1) studies are primarily based on
Western populations and we do not know if proposed BEC cut-off values (i.e. >300 cells·mm−3) can be
generalised for all populations; 2) the stability of eosinophil-low and eosinophil-high phenotypes has to be
established; 3) the impact of undiagnosed fungal and parasitic infections needs to be determined; and 4)
the effect of previous ICS treatment on BEC and its prognostic value need to be determined. PASCOE et al.
[34] presented data from the IMPACT trial which compared ICS/LAMA/LABA to ICS/LABA and LABA/
LAMA treatments. The authors concluded that increasing BECs were associated with increased ICS effects
on exacerbation on a continuous scale. MATHIOUDAKIS et al. [35] investigated the data from the ISOLDE
trial and confirmed that BEC is predictive for ICS response in ICS-naïve COPD patients [36].
Furthermore, direct ICS withdrawal from triple therapy led to increased risk of moderate/severe
exacerbations in patients with consistently high BECs in the SUNSET trial [37].
Markers predicting future mortality in COPD are warranted to identify patients at high risk who may
benefit from early interventions and close follow-up. WASCHKI et al. [38] presented results from the
COSYCONET cohort where serum high-sensitivity troponin I was evaluated in stable COPD patients and
it was found that serum levels >6 ng·L−1 were associated with all-cause mortality even after adjustment for
cardiovascular (CV) factors, body mass index (BMI), lung function, modified Medical Research Council
(mMRC) dyspnoea score and 6-min walk distance (6MWD) [39]. In addition, Agustí et al. [40] presented
data from the ECLIPSE cohort evaluating the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) 2017 disease groups (A, B, C and D) and their relation to mortality. The authors reported an
association between mortality and the highly symptomatic groups (B and D). This highlights the clinical
relevance of symptom assessment as an important therapeutic goal in COPD patients [41]. Furthermore,
PRUDENTE et al. [42] reported that BEC may have a long-term predictive value, as high BECs were
associated with increased 9-year mortality in a Brazilian cohort of COPD patients.
Markers identifying exacerbated COPD patients at high risk are also clinically important outside of stable
disease. According to the results of JØRGENSEN et al. [43], high serum soluble urokinase plasminogen
activator receptor (suPAR) may highlight patients with an increased risk for 30-day mortality.
Interestingly, PAPATHANASSIOU et al. [44] reported a significantly higher 1-year mortality in COPD patients
who had low BECs at hospital admission. In contrast, low blood eosinophil levels were associated with
lower rates of re-admission in a Russian study [45].
The new GOLD ABCD severity grading system
The updated GOLD 2017 classification of COPD severity grading generated debate and its impact was
evaluated by several studies presented at the Congress. Compared to GOLD 2013, GOLD 2017
recommends a simplified ABCD assessment tool, using only exacerbation history and respiratory
symptoms to guide treatment, while spirometry is used only for diagnosis and prognostic assessment [46].
Exclusion of spirometry from the ABCD assessment tool leads to the reclassification of a proportion of
patients from GOLD groups C and D to groups A and B. As a result, less intensive treatment is now
recommended for these patients, who have significantly affected pulmonary function (FEV1 <50%
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predicted) but do not experience frequent exacerbations or burdensome symptoms at stable state. This
approach is justified by the fact that currently available COPD pharmacotherapy targets respiratory
symptoms and exacerbations but cannot delay lung function decline or prevent mortality. Therefore, it is
anticipated that the newer GOLD classification will decrease the therapeutic burden of these patients
without affecting their clinical outcomes. Application of GOLD 2017 criteria in a cross-sectional study
involving over 19000 patients from the UK Clinical Practice Research Datalink (CPRD) led to
reclassification of 37% of all participants from groups C and D (according to GOLD 2013) to groups A
and B [47, 48]. Only 16% of all patients with COPD were classified as GOLD groups C or D according to
GOLD 2017, compared to 54% according to GOLD 2013 [47, 48]. A cross-sectional study in Poland
involving 2597 patients with COPD, as identified by primary care physicians, confirmed that the
application of GOLD 2017 leads to a decrease in patients allocated to GOLD groups C and D by 60% [49].
Less than 8% were classified as group C and 21% as group D. In the ECLIPSE cohort, only 7% and 15% of
all participants were allocated to GOLD groups C and D, respectively, compared to 23% and 40%
according to the GOLD 2013 classification [42]. Overall, application of GOLD 2017 criteria led to
reclassification of 25–60% of all patients with COPD who were previously graded as GOLD groups C or
D, but were now classified as GOLD groups A or B.
The recently published 2019 version of the GOLD document suggests that the ABCD system should be
used to guide the initial pharmacological management of COPD, while follow-up management should be
guided by a review-assess-adjust cycle [50]. The previously described studies evaluated patients who were
already receiving treatments that should have limited their symptoms and/or exacerbation burden.
Therefore, they must have underestimated the participants’ baseline ABCD grade (prior to treatment
initiation) and this is a limitation. However, GOLD 2019 also suggests that treatment de-escalation may be
needed in cases of ineffective treatment and side effects, but also of symptom resolution or overtreatment.
The aforementioned studies reveal a significant proportion of patients who do not experience
exacerbations and/or significant symptoms (GOLD groups A and B) and who are potentially overtreated,
mostly due to their previous classification as GOLD groups C and D. For example, in the UK CPRD
cohort, 22% and 43% of patients classified as GOLD stages A and B, respectively (26% of all patients with
COPD), were receiving triple therapy. These patients represent a prime target for a treatment de-escalation
trial aimed at limiting therapeutic burden and real-life data on the safety of de-escalation should be
assessed.
Spirometry, which is not included in the GOLD 2017 ABCD grading, is an accurate predictor of mortality.
For this reason, GOLD now suggests the use of the ABCD system to guide treatment, but the combination
of both the ABCD system and spirometry for prognostic evaluation [46]. A number of studies assessed the
predictive value of the ABCD system with regards to mortality. First, mortality was evaluated in the 784
participants of the real-life COPD cohort from the Czech Republic [51]. The shift of patients from GOLD
groups C and D to groups A and B when using GOLD 2017 resulted in an increase in the mortality rate
of group B (25% compared to 18.7% with GOLD 2011) and group C (23.1% compared to 17.9% with
GOLD 2011). Secondly, in the ECLIPSE cohort, GOLD 2017 classification resulted in a trend towards
increased mortality in all GOLD groups [40]. This suggests that the mortality rate of those reclassified was
lower than that of patients who were consistently in groups C or D and higher than that of those who
were consistently in groups A or B.
Bronchiectasis
Bronchiectasis is a highly complex condition characterised radiologically by the presence of pathological
dilation of the airway and clinically by persistent cough, sputum production, recurrent respiratory tract
infections and general malaise [52]. Bronchiectasis represents the final common pathway for a wide
number of disease processes and is associated with numerous aetiologies and comorbidities, as well as a
heterogeneous disease presentation, clinical course and response to treatment. The recently coined “vicious
vortex” depicts the underlying pathophysiological interplay driving airway dysfunction, inflammation,
infection and remodelling in bronchiectasis, with each pathophysiological process contributing to all the
others [53]. Rather than breaking the “vicious cycle”, which one would expect to halt disease progression,
treatments such as antibiotics may target only one component of the vortex with the remaining
components sustained by other stimuli, supporting the need for a multimodal therapeutic approach to this
condition [53].
At this year’s Congress, several large real-life cohort studies were presented using data from EMBARC, a
prospective dataset of more than 11000 patients from more than 27 European countries. Marked
heterogeneity in patient characteristics, management and outcomes were noted across different European
countries, with significantly worse QoL, faster lung function decline and higher exacerbation frequency
noted in Eastern Europe versus Western Europe, together with a significant between-country variability in
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access and referral to pulmonary rehabilitation [54, 55]. Classification of patients with nontuberculous
mycobacteria (NTM) and primary ciliary dyskinesia (PCD), conditions deserving of disease-specific
guidelines outside of bronchiectasis, showed older age, female sex, higher MRC dyspnoea scores and
bilateral involvement of the middle lobe and lingua to be independently associated with the development
of NTM in bronchiectasis, whilst PCD patients were typically younger at presentation with increased
disease severity compared to age and sex-matched patients with idiopathic disease or bronchiectasis
secondary to immune deficiency [56, 57]. Bronchiectasis associated with inflammatory bowel disease
(IBD), a recognised cause of bronchiectasis previously shown to be associated with a two-fold increase in
mortality, showed no significant differences with regards to bronchiectasis severity or lung function decline
and significantly lower rates of Pseudomonas colonisation in IBD patients compared to bronchiectasis due
to other causes (perhaps suggesting that IBD may be skewed towards a more inflammatory rather than an
infective pathophysiology) [58, 59]. An analysis of determinants of QoL in bronchiectasis showed sputum
production, breathlessness, exacerbations and chronic infection with Pseudomonas or NTM to be the
greatest contributors to QoL burden [60]. Data from the Severe Asthma Network Italy (SANI) cohort
showed that severe asthma patients with bronchiectasis had significantly reduced lung function, asthma
control and QoL, with a higher exacerbation and hospitalisation frequency compared to those without
bronchiectasis, suggesting a possible new phenotype [61].
Several high quality studies focusing on the science behind the disease were also presented, with
multicentre studies looking at the effects of GORD and immune-allertypes in bronchiectasis as potential
new disease endotypes. Having previously been shown to increase mortality 2.5-fold, proteomics analysis
of bronchiectasis patients with GORD demonstrated increased markers of epithelial injury and an
increased defence response to bacterium, correlating with increased exacerbations and worse QoL
compared to GORD-negative patients [59, 62]. Exploration of the role of allergy and sensitisation in
bronchiectasis demonstrated a fungal driven immune-allertype to be associated with more severe disease
and poorer lung function [63]. These are potentially treatable traits for a disease where limited treatment
options currently exist.
BEDI et al. [64] showed that a pro-inflammatory mediator profile associated with dysregulation of LXA4
biosynthetic genes contributes to persistent infection in bronchiectasis. In addition, the Chalmers group
showed that antimicrobial peptides and airway bacterial colonisation may be important in the pathogenesis
of airway infection in bronchiectasis and that patients with severe bronchiectasis have reduced AMPK
activation in sputum neutrophils, which may be associated with a significant reduction in ciliary beat
frequency [65, 66]. Further work from this group showed a heterogeneous response of neutrophil
phagocytosis to sputum supernatant, suggesting that airway factors inhibit neutrophil phagocytosis in
some patients, resulting in worse brief symptom inventory (BSI) scores and poorer QoL [67]. Abnormal
sputum rheology was observed in bronchiectasis airways compared to healthy airways but, perhaps
surprisingly, no differences in sputum elasticity, viscosity or stiffness were noted in bronchiectasis patients
with Pseudomonas aeruginosa (PA) versus those without [68, 69].
No approved therapies currently exist for bronchiectasis and many clinical trials have failed to meet their
primary endpoints because of heterogeneous treatment responses and the inherent difficulty of identifying
patients likely to respond. Post hoc analyses of ORBIT-3 and ORBIT-4 show that ARD-3150 (liposomal
ciprofloxacin) is particularly effective in patients with four or more exacerbations in the previous year[70].
Similarly, serial Kaplan–Meier analyses showed the beneficial impact of ARD-3150 to be apparent from
the third exacerbation in ORBIT-3 and for all serial exacerbations in ORBIT-4 [71]. Furthermore, the
efficacy and safety profile was maintained during open-label extension [72].
While new therapies are welcomed, many are antibiotic-related and thus carry the risk of antibiotic resistance.
Resistance acquisition was reported to occur with one in four bronchiectasis patients in a prospective
observational multicentre study in Italy and Spain, with a correlating higher number of exacerbations and
hospitalisations [73]. Whether this effect is maintained or intermittent requires further investigation.
Although disease phenotyping and endotyping are in their infancy in bronchiectasis they hold therapeutic
promise for patients, leading towards our ultimate goal of administering more specialised and personalised
medication.
Small airways
It is well established that the small airways are the major site of airway obstruction in COPD and in recent
years have also been highlighted as a promising target for improving treatment outcomes in patients with
poorly controlled asthma. The important role that small airways play in asthma was highlighted by Paul
O’Byrne in a talk within an industry sponsored session. Professor O’Byrne indicated that airflow
measurements such as FEV1 (which measure airflow in the larger airways) do not tend to correlate with
https://doi.org/10.1183/23120541.00225-2018 6
AIRWAY DISEASE | F. SCHLEICH ET AL.
disease severity, whereas uncontrolled asthma is associated with persistent small airways disease. Targeting
the small airways through utilisation of extrafine particles, which have shown promising results in several
studies, may be the key to improved asthma control.
The ERS also showcased the upcoming outcomes of the Assessment of Small Airways Involvement In
Asthma (ATLANTIS) project. This project aims to better understand the role of small airways disease in
asthma through determining the role of the small airways in clinical manifestations and to determine the
best combination of diagnostic tests to apply [74]. Furthermore, the study has allowed further development
and validation of a questionnaire specifically designed for assessing small airways disease [75]. Thanks to
the collaborative work of a multinational consortium, the ATLANTIS study has shown for the first time
how small airway abnormalities drive the clinical expression of asthma, both in a cross-sectional and a
longitudinal manner, and results should help to optimise future patient care in asthma.
One key problem in investigating the role of the small airways in the pathophysiology of airway disease is
effectively and accurately assessing their function. OSTRIDGE et al. [76] presented a novel quantitative
computed tomography (CT) method, disease probability measure (DPM), to assess the contribution of
small airways disease in COPD. DPM measures pulmonary lobe density using inspiratory and expiratory
images to measure the extent of air trapping. Patients were scanned and assessed as “normal”,
“emphysemous”, or “gas trapping” due to small airway disease. Significantly more air trapping was found
in COPD patients than in healthy subjects, ex-smokers and current smokers. This is a novel, precise way of
measuring small airway contribution to disease pathology.
Potential causes of small airway disease development were also investigated and TANABE et al. [77] looked
at the role that serine proteases may play in contributing to small airways disease. Lung tissues were
collected from patients with COPD (GOLD stage 2) and asymptomatic control smokers and these were
fixed and stained to measure protease activity. Interestingly, protease activity was significantly higher in
COPD patients compared to control subjects and this may, therefore, be one of the factors behind airway
remodelling. This finding prompted the authors to conclude that serine protease inhibitors might
represent a potential therapeutic strategy against small airways disease in COPD.
As the small airways contribute significantly to the pathophysiology of asthma and COPD, many abstracts
examined the optimal delivery method for therapies directly to them. BIDDISCOMBE et al. [78] compared the
effect of tiotropium delivered from two different devices (a dry powder inhaler (DPI) and the slow mist
inhaler (SMI) Respimat™) in 44 mild to moderate COPD patients. Physiological measures of both the
small and large airways were taken to determine which device was better suited to delivering drugs to the
lung periphery. Results showed that only the tiotropium SMI significantly improved small airway function
and, furthermore, that it also positively impacted on large airway parameters, indicating that SMI
formulation may be best at targeting both the large and small airways.
Electronic health (e-Health)
The digital evolution in respiratory medicine as an innovative and personalised approach [79] was
depicted by Omar Usmani in a highly attended symposium. In particular, the speaker presented the study
protocol [80, 81] and the preliminary findings of a multicentre, Horizon 2020 European Union funded
project started on January 2015 which is close to completion (www.myaircoach.eu/myaircoach/).
One of the main goals of the project is to help patients to manage their asthma through a personalised
e-Health approach, using user-friendly tools to increase patients’ awareness of their clinical state, as well as
adherence to medical treatments and the effectiveness thereof. MyAirCoach sensors have been monitoring
and storing several physiological, behavioural and environmental parameters which will be analysed and
crossed with asthma data. Thanks to sophisticated computational modelling techniques, MyAirCoach will
be able to provide measurements, features, indicators and personal profile data to give a picture of a
patient’s condition and ensure clinical state awareness and optimal treatment. In the near future,
healthcare professionals could use MyAirCoach to supervise the condition of their patients and adjust
their prescribed medication accordingly. MyAirCoach will provide clinicians with early indications of
increasing asthma symptoms or exacerbations, while helping to understand the mechanisms underpinning
the progression of the disease. The impact of MyAirCoach is expected to set the basis for the widespread
adoption of e-Health self-management systems across the spectrum of respiratory diseases.
Airway sensory nerves and cough
Cough is a reflex event initiated following activation of airway sensory nerves and is a major symptom of
airway diseases such as asthma and COPD; however, it can also be idiopathic in origin [82]. When cough
lasts for more than 8 weeks it is known as chronic cough, which is a major unmet medical need that
lowers the QoL of sufferers [83]. The cough reflex was again a topic of great interest at Congress,
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highlighted by the number of extremely well attended abstract sessions dedicated to cough or neural
control of the airways and also a symposium entitled “Towards understanding and managing chronic
cough”, which contained lectures from many well-known names in the cough field.
Airway sensory nerves housed within the vagus nerve initiate airway reflexes such as cough [84] and a
number of studies highlighted the potential role of neuronal remodelling in the pathogenesis of cough and
airway hyperresponsiveness (AHR) in airway disease. An abstract by BLUM et al. [85] utilised
bronchoscopic biopsies from subjects with healthy control and immunolabelled sections for nerves and
eosinophils. The authors showed that the samples from chronic cough patients had a doubling of nerve
length as well as increased numbers of branch points compared to healthy controls and suggest that
increased sensory nerve density may underlie the development of cough hypersensitivity. A further study
presented by KISTEMAKER et al. [86] utilised ovalbumin (OVA) sensitised mice that were challenged either
acutely or chronically. AHR was then measured in control and vagotomised subjects, and contraction to
methacholine (MCh) and electrical field stimulation (EFS) were measured in lung slices. The authors
showed that following chronic OVA challenge, AHR in vagotomised animals was attenuated and protein
gene product 9.5 (PGP 9.5) expression was increased; however, there were no changes following acute
challenge. Furthermore, EFS-induced contraction was increased but MCh-induced contraction remained
unchanged with an increase of brain-derived neurotrophic factor (BDNF) expression in lung tissue. These
studies indicate that airway sensory nerves may contribute to the pathogenesis of airway diseases, along
with the increased cough hypersensitivity seen and they highlight a novel target for treatment.
Receptors on airway sensory nerves are key targets for the treatment of neuronally driven symptoms such
as cough. CHEN et al. [87] presented an abstract looking at the activation of an oxidant sensor ion channel,
transient receptor potential ankyrin 1 (TRPA1), on sensory nerves. Using vagus nerves from humans,
guinea pigs and TRPA1-knockout mice it was shown that there are a number of activators of TRPA1, both
endogenous (e.g. the disease-relevant mediator prostaglandin E2 (PGE2)) and exogenous (e.g. acrolein),
which can work to activate the channel via distinct mechanisms. CHEN et al. showed that PGE2 activated
TRPA1 through the activation of NADPH oxidase, but acrolein is a more direct cause of reactive oxygen
species (ROS) as activation was inhibited by N-acetylcysteine (NAC). This highlights different modalities
of TRPA1 activation which may provide targets for treatment. In addition, WORTLEY et al. [88] were able to
show that a key asthma treatment, β-agonists, can inhibit airway sensory nerve activation and cough in a
guinea pig model. Furthermore, this effect is not lost with chronic treatment, unlike the effect on
bronchoconstriction, highlighting that β-agonists may still be a useful long-term treatment for cough even
when efficacy is reduced against bronchoconstriction.
The P2X3 inhibitor MK7624 has been shown to be the most promising novel cough therapeutic in recent
years, with a preliminary study [89] indicating that it was able to cause a 75% reduction in daytime cough
frequency, albeit with a side effect of taste disturbance. SMITH et al. [90] presented an update on MK7624,
investigating efficacy responses and evaluating baseline and demographic characteristics. The primary end
point of this study was awake cough frequency (ACF) and, from 253 patients, the authors showed that
ACF was significantly reduced by MK7624 and also that ACF was lower in the USA compared to the UK.
BIRRING et al. [91] presented a further abstract on cough demographics that looked at patient characteristics
and triggers eliciting refractory chronic cough. The research indicated that those suffering from treatment
refractory chronic cough were mostly female of middle/older age. Furthermore, although cough triggers
were unpredictable, a high proportion of triggers were associated with neuronal hypersensitivity. These
studies highlight that patients demographics are an important factor when evaluating the efficacy of novel
cough therapeutics.
Along with the number of high quality abstracts addressing the problem of chronic cough, cough has
further been highlighted by the creation in 2018 of a novel ERS Taskforce. This is a clinical research
collaboration entitled “Neurocough: new understanding in the treatment of chronic cough”, a
pan-European multicentre network that aims to improve the management of cough.
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